NCT04246814

Brief Summary

Diabetes mellitus (DM) is currently an important cause of morbidity and mortality. Global estimates indicate that 382 million people live with diabetes (8.3%), and that number could reach 592 million in 2035. The diabetic foot ulcers (DFU) present as sore wounds with disintegration of the skin. The DFU affect 15% of diabetic patients. Several studies have been conducted aiming to find therapeutic strategies for the healing of DFU, among the reported therapeutic methods the Low-level Laser Therapy (LLLT) has been highlighted. The aim of this study is to investigate the effects of different doses of LLLT in the treatment of DFU. Methods: This study is characterized as a double-blind randomized clinical trial (RCT), consisting of four groups, the control group will have only dressing and placebo LLLT application and the other three groups will have dressing and real LLLT GaAs 904 nm application. Expected outcomes: to elucidate the effects of different doses of LLLT GaAs 904 nm on the treatment of DFU, beyond to identify the most effective dose.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 27, 2019

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 22, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 29, 2020

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 18, 2021

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 18, 2023

Completed
Last Updated

February 22, 2024

Status Verified

February 1, 2024

Enrollment Period

2 years

First QC Date

January 22, 2020

Last Update Submit

February 21, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in the ulcer area

    Measure of ulcer area change.

    Before intervention starts, 5th and 10th week of intervention.

  • Change in complete ulcer healing

    Change in the percentage of complete ulcer healing.

    Before intervention starts, 5th and 10th week of intervention.

Secondary Outcomes (4)

  • Wagner Classification

    Before intervention starts, 5th and 10th week of intervention and after 1 month and after 1 month.

  • Blood glucose

    Before intervention starts, 5th and 10th week of intervention and after 1 month and after 1 month.

  • Temperature

    Before intervention starts, 5th and 10th week of intervention.

  • Short Form-36 Health Survey questionnaire

    Before intervention starts, 5th and 10th week of intervention and after 1 month and after 1 month.

Study Arms (4)

CC + dressing

PLACEBO COMPARATOR

The group will receive placebo LASER application associated with Helianthus annuus oil dressing.

Device: CCProcedure: Dressing

LG1 + dressing

ACTIVE COMPARATOR

The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 10 J/cm² associated with Helianthus annuus oil dressing.

Device: LG1Procedure: Dressing

LG2 + dressing

ACTIVE COMPARATOR

The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 8 J/cm² associated with Helianthus annuus oil dressing.

Device: LG2Procedure: Dressing

LG3 + dressing

ACTIVE COMPARATOR

The group will receive application of LASER Gallium Arsenide (GaAs) 904 nm 4 J/cm² associated with Helianthus annuus oil dressing.

Device: LG3Procedure: Dressing

Interventions

LG1DEVICE

Application of LASER AsGa 904nm 10 J/cm².

LG1 + dressing
LG2DEVICE

Application of LASER AsGa 904nm 8 J/cm².

LG2 + dressing
LG3DEVICE

Application of LASER AsGa 904nm 4 J/cm².

LG3 + dressing
CCDEVICE

Application of placebo LASER.

CC + dressing
DressingPROCEDURE

Application of Helianthus annuus oil dressing.

CC + dressingLG1 + dressingLG2 + dressingLG3 + dressing

Eligibility Criteria

Age18 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes mellitus patients with diabetic foot ulcers;
  • Patients aged 18 and over.

You may not qualify if:

  • Type 2 diabetes mellitus patients with ulcers in parts of the body other than the feet;
  • Patients with infected diabetic foot ulcers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Federal University of Piaui

Parnaíba, Piauí, 64202-020, Brazil

Location

Related Publications (2)

  • Saura Cardoso V, de Souza Lima da Silveira PR, Dos Santos CM, Miranda MB, Silva Barros AC, Veloso LC, Magalhaes AT, da Rocha RB, Hazime FA. Dose-response and efficacy of 904 nm photobiomodulation on diabetic foot ulcers healing: a randomized controlled trial. Lasers Med Sci. 2024 May 28;39(1):142. doi: 10.1007/s10103-024-04090-3.

  • Cardoso VS, de Souza Lima da Silveira PR, Dos Santos CM, da Rocha RB, Hazime FA. Dose-response and efficacy of low-level laser therapy on diabetic foot ulcers healing: Protocol of a randomized controlled trial. Contemp Clin Trials. 2021 Nov;110:106561. doi: 10.1016/j.cct.2021.106561. Epub 2021 Sep 4.

MeSH Terms

Conditions

Diabetic Foot

Interventions

Bandages

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Intervention Hierarchy (Ancestors)

Equipment and Supplies

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Masking will be double-blind, the volunteer and outcome assessor will not be aware of the individual allocation of participants in the intervention groups.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Professor of the Graduate Program in Biomedical Sciences

Study Record Dates

First Submitted

January 22, 2020

First Posted

January 29, 2020

Study Start

August 27, 2019

Primary Completion

August 18, 2021

Study Completion

August 18, 2023

Last Updated

February 22, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations